EANM’14 – Mini Course 1
October 19, 2014, 14:30 – 15:30
Updates in PET Radiopharmaceuticals
Chairpersons: B. Vidovic (Munich), M. Sadik (Gothenburg)
|J. Ballinger (London):
New PET Radiopharmaceuticals: Clinical Applications and Pharmaceutical Quality Assurance
|S. Boschi (Bologna):
New PET Radiopharmaceuticals: From Clinical Needs to Pharmaceutical Quality
- New PET Radiopharmaceuticals
- Assessing Product Quality (QA)/Pharmaceutical Quality
- Learn about Staff Radiation Protection in Production PET Radiopharmaceuticals
- Changes in Image Quality
- Pharmaco-toxicological Effects
More than twenty years after its inception, [18F]FDG- is still the most widely used radiopharmaceutical for PET studies, but numerous more specific radiotracers have been developed and applied in neuroscience, cardiology, and oncology. The advances in radiotracer chemistry, especially the nucleophilic substitution reaction, have played the pivotal role in synthesising various no-carrier-added 18F-labeled radiotracers for PET studies of various receptor systems.
An encouraging trend is that researchers are actively developing new PET agents that will extend its range beyond tissue metabolism. The objective is to characterise diseased tissue more accurately at an earlier stage so that effective drugs can be used for treatment.
[18F]FDG, Radiopharmaceutical, PET Studies, Radiotracers